Strain construction method for promoting de novo synthesis of mogroside v from yeast, and use
By integrating exogenous genes into the yeast genome and utilizing metabolic engineering and lipid droplet localization technology, the problems of instability and low efficiency in the de novo synthesis of mogroside V from yeast were solved, achieving efficient and stable production of mogroside V, increasing yield by 5 times and shortening the cycle by half.
Patent Information
- Application Number
- PCT/CN2025/094444
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2025-05-13
- Publication Date
- 2026-11-12
AI Technical Summary
In existing technologies, the de novo synthesis of mogroside V from yeast suffers from problems such as gene dependence on plasmids leading to production instability, dispersibility of pathway enzymes in subcellular localization, low squalene utilization, and low P450 enzyme catalytic efficiency, which limit the yield and production efficiency of mogroside V.
By integrating exogenous genes into the yeast genome, regulating yeast through metabolic engineering, combining CRISPR Cas9 gene editing and lipid droplet localization technology, enhancing the expression pathway enzymes, and improving catalytic efficiency through enzyme fusion expression and cofactor supply, the de novo synthesis of mogroside V by yeast was achieved.
Without relying on plasmids, the yield and production efficiency of mogroside V were significantly improved, with a yield of 26.33 mg/L, a production cycle shortened to 48 h, and significant improvements in stability and efficiency.
Smart Images

Figure CN2025094444_12112026_PF_FP_ABST
Abstract
Description
A method for constructing and applying a yeast strain that promotes de novo synthesis of mogroside V. Technical Field
[0001] This invention relates to a method for constructing engineered yeast, and more particularly to a method for constructing and applying a yeast strain that promotes de novo synthesis of mogroside V. Background Technology
[0002] Mogroside V is a non-toxic, natural tetracyclic triterpenoid glycoside derived from mogroside fruit, with the chemical formula C. 60 H 102 O 29 With a relative molecular mass of 1287.43, this substance is formed by the dehydration condensation of glucose residues linked to the hydroxyl groups at positions C-3 and C-24 of mogroside, resulting in a structure containing a total of 5 glucose residues. This structure contributes to the extremely high sweetness of mogroside V; its 0.1% aqueous solution is approximately 250 times sweeter than a sucrose solution, making it the primary source of the sweetness of mogroside. Furthermore, mogroside V is calorie-free and will not cause diabetes or obesity; it is non-fermentable and does not cause tooth decay; mogroside V also has beneficial effects such as regulating blood sugar and blood pressure, protecting nerves, reducing inflammation, and activating the immune system. These advantages make mogroside V a promising sugar substitute, and its widespread application aligns with the World Health Organization's plan for the prevention and control of non-communicable diseases.
[0003] However, the cultivation cycle of monk fruit is long, the planting area is limited, and plant growth depends on climate and soil. Monk fruit glycoside V accounts for less than 1% of the fruit's dry weight, resulting in extremely low yields of monk fruit glycoside V obtained through extraction. Furthermore, the substance has a complex structure, making chemical synthesis difficult. The combination of synthetic biology and metabolic engineering makes the construction of cell factories feasible. Therefore, converting inexpensive carbon sources into monk fruit glycoside V through fermentation is a promising method for reducing costs and efficiently obtaining the product. Currently, the synthetic pathway of monk fruit glycoside V has been elucidated, and researchers have integrated epoxidase, epoxidase, cytochrome P450 enzyme, cytochrome P450 reductase, and glycosyltransferase genes into the genome of *Saccharomyces cerevisiae*. By enhancing the expression of the rate-limiting enzyme in the mevalonate pathway and enhancing the expression of squalene epoxidase, they achieved de novo synthesis of monk fruit glycoside V in yeast.
[0004] Current methods rely on plasmids for high copy expression of some genes, which can lead to production instability. Furthermore, there is still significant room for improvement in the yield of mogroside V. Problems exist in the construction of cell factories, including the dispersion of pathway enzymes at subcellular locations, low squalene utilization, and low catalytic efficiency of P450 enzymes. Summary of the Invention
[0005] The technical problem to be solved by this invention is to provide a method for constructing a recombinant yeast strain that promotes the de novo synthesis of mogroside V. This method involves integrating a foreign gene into the yeast genome and regulating and modifying the yeast through metabolic engineering to promote the efficient de novo fermentation synthesis of mogroside V using glucose as a substrate.
[0006] Specifically, a method for constructing a yeast strain that promotes de novo synthesis of mogroside V involves constructing a gene expression frame P. GAL1 -PLN1-linker-EPH3-T CYC1 P GAL1 -PLN1-linker-CYP87D18-T CYC1 P GAL1 -PLN1-linker-AtCPR2-T CYC1 P GAL1 -PLN1-linker-UGT74MG1-T CYC1 P GAL1 -PLN1-linker-UGTMS1 M7 -T CYC1 Recombinant engineered yeast strains were obtained by inserting their genomes into the genomes of yeast strains that have integrated pathway enzymes and enhanced expression of the mevalonate pathway and squalene epoxidase.
[0007] The pathway enzymes include cucurbitacinol synthase CDS (amino acid sequence NCBI ID: AUC64917.1); the epoxide hydrolase EPH3 (amino acid sequence as shown in SEQ ID NO.1); cytochrome P450 enzyme CYP87D18 (amino acid sequence NCBI ID: K7NBR2.1); cytochrome P450 enzyme reductase AtCPR2 (amino acid sequence NCBI ID: UTD45115.1); and glycosyltransferases UGT74MG1 and UGTMS1. M7 (The amino acid sequences are shown in SEQ ID NO.2 and SEQ ID NO.3, respectively).
[0008] Among them, gene expression box P GAL1 -PLN1-linker-EPH3-T CYC1 Insert the gene into the 720a site of the recombinant engineered yeast strain, and insert the gene expression cassette P into SAP155b. GAL1 -PLN1-linker-CYP87D18-T CYC1 Gene expression cassette P was inserted at site 1414a. GAL1 -PLN1-linker-AtCPR2-T CYC1 Gene expression cassette P was inserted at site 1260a. GAL1-PLN1-linker-UGT74MG1-T CYC1 Gene expression cassette P was inserted at site 805a. GAL1 -PLN1-linker-UGTMS1 M7 -T CYC1 .
[0009] To overcome the problem of subcellular localization and dispersion of pathway enzymes and promote the continuity of catalytic reactions, exogenous enzymes were expressed in compartmentalized form within lipid droplets. The endogenous lipid droplet membrane protein PLN1 from Saccharomyces cerevisiae was used as the localizing protein, and a flexible linker protein was used as the connecting protein to fuse the localizing protein to the N-terminus of the pathway enzyme.
[0010] Furthermore, to promote proper protein folding, the endoplasmic reticulum regulatory gene PAH1 in the recombinant engineered yeast was knocked out using the CRISPR Cas9 gene editing method, and the intrinsic promoter P of INO2 was removed. INO2 Replace with constitutive strong promoter P TEF1 And the inherent promoter P of ICE2 ICE2 Replace with constitutive strong promoter P TEF1 This is to achieve an expansion of the endoplasmic reticulum area.
[0011] Furthermore, to overcome the problems of low expression levels and low catalytic efficiency of the P450 enzyme, the gene expression cassette P of the fusion enzyme was inserted into the transposition site ty1 of the recombinant engineered yeast strain. GAL1 -PLN1-linker-AtCPR2-linker-CYP87D18-T CYC1 The strain with the highest yield of mogroside V was selected from the correctly verified transformants.
[0012] To further enhance the utilization rate of squalene, squalene cyclooxygenase was linked to the localization protein oleosin, and the expression of the cofactor FAD synthase FAD1 was enhanced. The expression cassette P... TEF1 -ERG1-linker-oleosin-linker-FAD1-T CYC1 Insert the IGR13 site into the strain that produces the highest yield of mogroside V.
[0013] The engineered yeasts of this invention include, but are not limited to, Saccharomyces cerevisiae, Pichia pastoris, Pichia fermentata, Hansenula anomala, Yersinia lipolytica, Candida antarctica, Candida utilis, Candida tropicalis, Schizosaccharizoi saccharizoi, and Rhodotorula glutinis.
[0014] In this invention, the cucurbitacinol synthase CDS (amino acid sequence NCBI ID: AUC64917.1); the epoxide hydrolase EPH3 (amino acid sequence as shown in SEQ ID NO.1); the cytochrome P450 enzyme CYP87D18 (amino acid sequence NCBI ID: K7NBR2.1); the cytochrome P450 enzyme reductase AtCPR2 (amino acid sequence NCBI ID: UTD45115.1); and the glycosyltransferases UGT74MG1 and UGTMS1 are included. M7 (The amino acid sequences are shown in SEQ ID NO.2 and SEQ ID NO.3, respectively). Furthermore, this invention relates to the localization protein PLN1, wherein the protein used for localizing exogenous enzymes is the endogenous lipid droplet membrane protein PLN1 from *Saccharomyces cerevisiae* (amino acid sequence NCBI ID: NP_012972.3). The localization protein used for localizing endogenous squalene epoxidase from *Saccharomyces cerevisiae* is the corn-derived oil body storage protein oleosin (amino acid sequence NCBI ID: PWZ10044.1). The amino acid sequence of the linker protein is (GGGGGS)2.
[0015] Furthermore, the gene encoding the mogroside synthesis pathway is integrated and expressed using CRISPR Cas9 editing technology.
[0016] The P GAL1 It is an endogenous promoter of *Saccharomyces cerevisiae*, and its nucleotide sequence is shown in SEQ ID NO.4. Promoter P TEF1 It is an endogenous constitutive promoter of Saccharomyces cerevisiae, and its nucleotide sequence is shown in SEQ ID NO.5.
[0017] The terminator T CYC1 It is an endogenous terminator of Saccharomyces cerevisiae, and its nucleotide sequence is shown in SEQ ID NO.6.
[0018] The present invention also provides a recombinant yeast strain that promotes the de novo synthesis of mogroside V by yeast, obtained by the above construction method.
[0019] This invention also provides the application of the above-mentioned recombinant yeast strain that promotes the de novo synthesis of mogroside V, specifically its application in the bio-fermentation production of mogroside.
[0020] In this invention, the method for producing mogroside V by fermentation of the recombinant yeast strain is as follows: the recombinant yeast strain that promotes the de novo synthesis of mogroside V is taken and cultured in liquid YPD medium at 30°C and 220 r / min for 18 h in a shaker to obtain a fermentation seed liquid; the fermentation seed liquid is transferred into the fermentation medium at an inoculation rate of 2% and cultured at 30°C and 220 r / min for 96 h.
[0021] The beneficial effects of this invention are:
[0022] 1. The method for constructing recombinant Saccharomyces cerevisiae provided by this invention can promote the fermentation of glucose as a substrate to produce mogroside V without relying on plasmids, and overcomes the inherent production bottleneck of cell factories. The product can be secreted extracellularly, laying a good foundation for downstream separation and purification steps. The method for constructing recombinant Saccharomyces cerevisiae provided by this invention is simple, the obtained strain is stable, and the fermentation cycle is short, showing good prospects.
[0023] 2. This invention further enhances the production of mogroside V by employing different strategies, building upon existing yeast cell factories that produce mogroside V. The final strain (M11) achieved a mogroside V yield of 26.33 mg / L, approximately five times that of the strain (M07) initially capable of synthesizing mogroside V. The fermentation cycle of the final strain (M11) was 48 hours, half that of M07 (96 hours). Attached Figure Description
[0024] Figure 1 shows the yield of mogroside V.
[0025] Figure 2 shows the changes in intracellular squalene.
[0026] Figure 3 shows the variation of mogroside V with fermentation time. Detailed Implementation
[0027] Specific embodiments of the present invention will now be described in more detail. These embodiments are provided so that this invention will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
[0028] The detection method of this invention embodiment:
[0029] Collect the fermentation broth, centrifuge at 8000 rpm for 5 min, take 1 mL of the supernatant and add chromatographic grade formic acid to achieve a final formic acid concentration of 3% (v / v). Let stand at 4℃ for 4-8 h to remove protein, centrifuge at 8000 rpm for 5 min, take 0.5 mL of the supernatant, filter through a 0.22 μm aqueous filter membrane and add to a liquid chromatography analysis bottle for yield determination.
[0030] The detection method of this invention embodiment:
[0031] High performance liquid chromatography-mass spectrometry (LC-MS) detection method: Agilent Infinity LabPoroshell 120 HILIC column, mobile phase A - acetonitrile with 0.1% formic acid solution and B - 0.1% formic acid aqueous solution, column temperature 30℃, injection volume 1μL.
[0032] Example 1: Overcoming steric hindrance of pathway enzymes to promote the production of mogroside V by engineered strains
[0033] The construction of the engineered Saccharomyces cerevisiae strain M07 is described in CN2024100456198, and its construction is as follows:
[0034] Based on the amino acid sequences of key enzymes involved in the synthesis of mogrosides published on NCBI or from references, the enzymes include: cucurbitacin synthase CDS (NCBI ID: AUC64917.1); epoxidase EPH3, with the amino acid sequence shown in SEQ ID NO.1; cytochrome P450 enzyme CYP87D18 (NCBI ID: K7NBR2.1); cytochrome P450 enzyme reductase AtCPR2 (NCBI ID: UTD45115.1); glycosyltransferase UGT74MG1, with the amino acid sequence shown in SEQ ID NO.2; and glycosyltransferase UGTMS1. M7 The amino acid sequence is shown in SEQ ID NO.3.
[0035] The truncated 3-hydroxy-3-methylglutaryl-CoA reductase tHMG1 is formed by removing the transmembrane domain consisting of amino acids 2-530 from the N-terminus of the endogenous enzyme HMG1 in Saccharomyces cerevisiae. The 3-hydroxy-3-methylglutaryl-CoA synthase gene (ERG13), squalene synthase gene (ERG9), and squalene epoxidase gene (ERG1) are all endogenous genes of S. cerevisiae.
[0036] Constructing gene expression frames includes ①P TEF1 -CDS-T CYC1 ②P TEF1 -EPH3-T CYC1 ③T TDH3 -CYP87D18-P GAL1 / 10 -ATCPR2-T CYC1 , ④T ADH1 -UGT74MG1-P GAL1 / 10 -UGTMS1 M7 -T CYC1 ⑤P TEF1 -tHMG1-T CYC1 ⑥P TEF1 -ERG1-T CYC1 Expression frames ①-⑤ were transformed into the genomes of the host strains *S. cerevisiae* CEN PK2-1C MATa; URA3-52; TRP1-289; LEU2-3,112; HIS3Δ1; MAL2-8C; and SUC2; and then transformed using the constitutive strong promoter P. TEF1The original promoters of ERG13 and ERG9 on the genome were replaced; finally, the expression cassette ⑥ was integrated into the yeast genome to obtain strain M07. The specific integration method and site are described in reference [1].
[0037] The fragments of engineered Saccharomyces cerevisiae strain M07 were pretreated by ultracentrifugation, and different cellular components were separated and collected. Liquid chromatography analysis revealed that 2,3-epoxysqualene, the precursor of mogroside V, was mainly encapsulated in lipid droplets, with very low concentrations in other cellular components. Therefore, to overcome steric hindrance between pathway enzymes and promote reaction continuity, the pathway enzymes were expressed in compartmentalized form within lipid droplets. Using annotations from the NCBI database, endogenous lipid droplet membrane proteins from Saccharomyces cerevisiae were selected as localizing proteins to achieve the compartmentalization of the pathway enzymes. The codon-optimized epoxidase EPH3 was then amplified using primers. [2] Cytochrome P450 enzyme CYP87D18 (NCBI ID: K7NBR2.1), cytochrome P450 enzyme reductase AtCPR2 (NCBI ID: UTD45115.1), glycosyltransferase UGT74MG1 [3] UGTMS1 M7[4] Using the endogenous lipid droplet membrane protein PLN1 from *Saccharomyces cerevisiae* as the localizing protein and a flexible linker protein as the connecting protein, the localizing protein was fused to the N-terminus of the pathway enzyme. The endogenous lipid droplet localizing protein from *Saccharomyces cerevisiae* was amplified, and the promoter P was amplified accordingly. TEF1 P GAL1 Termination of sub-T CYC1 Homologous arms of loci 720a, SAP155b, 1414a, 1206a, and 805a were amplified. Gene expression cassettes were constructed using overlap-derived PCR, and then connected to the corresponding homologous arms to construct linear gene fragments.
[0038] The primers used to construct the expression cassette and amplify the homologous arms are shown in Table 1. The PCR conditions are shown in Table 2.
[0039] Table 1 Primers required for amplification fragments
[0040] Table 2 PCR amplification conditions
[0041] The constructed gene expression frames are as follows: P GAL1 -PLN1-linker-EPH3-T CYC1 P GAL1 -PLN1-linker-CYP87D18-T CYC1 P GAL1-PLN1-linker-AtCPR2-T CYC1 P GAL1 -PLN1-linker-UGT74MG1-T CYC1 P GAL1 -PLN1-linker-UGTMS1 M7 -T CYC1 .
[0042] The expression box P GAL1 -PLN1-linker-EPH3-T CYC1 Insertion at site 720a of strain M1 yields strain M2.
[0043] Starting with strain M2, gene expression cassette P was inserted into SAP155b. GAL1 -PLN1-linker-CYP87D18-T CYC1 strain M3 was obtained.
[0044] Starting with strain M3, gene expression cassette P was inserted at site 1414a. GAL1 -PLN1-linker-AtCPR2-T CYC1 Strain M4 was obtained.
[0045] Starting with strain M4, gene expression cassette P was inserted at site 1260a. GAL1 -PLN1-linker-UGT74MG1-T CYC1 Strain M5 was obtained.
[0046] Starting with strain M5, gene expression cassette P was inserted at site 805a. GAL1 -PLN1-linker-UGTMS1 M7 -T CYC1 Strains M6 were obtained.
[0047] The primers for amplifying homologous arms are shown in Table 3. The PCR conditions are shown in Table 2.
[0048] A CRISPR Cas9 sgRNA plasmid was constructed. Using plasmid pML104 as a template, circular PCR was performed with primers containing a 20bp PAM sequence. The plasmid pML104-PAM-Cas9 with the corresponding PAM sequence was obtained by sequencing.
[0049] The primers required for constructing the pML104-PAM-Cas9 plasmid are shown in Table 3. The PCR conditions are shown in Table 2.
[0050] The constructed pML104-PAM and gene expression cassette were transformed into competent cells of Saccharomyces cerevisiae host strain M5. Transformants with correct colony PCR results were selected for sequencing verification, and finally, recombinant Saccharomyces cerevisiae strain M6 with compartmentalized expression pathway enzymes was obtained.
[0051] Table 3 Primers required for constructing plasmids containing the PAM region.
[0052] The references mentioned are:
[0053] [1] Guilin Rhein Synthetic Biotechnology Co., Ltd., Jiangnan University. A method for constructing an engineered yeast for de novo synthesis of mogrosides: CN202410045619.8[P].
[0054] [2] Itkin, M.; Davidovich-Rikanati, R.; Cohen, S., et al., The biosynthetic pathway of the nonsugar, high-intensity sweetener mogroside V from Siraitiagrosvenorii. Proc. Natl. Acad. Sci. USA 2016, 113(47), E7619-E7628.
[0055] [3]Li,J.;Mu,S.;Yang,J.,et al.,Glycosyltransferase engineering and multi-glycosylation routes development facilitating synthesis of high-intensity sweetener mogrosides.iScience 2022,25(10),105222.
[0056] [4]Li,J.,Yang,J.,Mu,S.,et al.,Efficient O-glycosylation of triterpenes enabled by protein engineering of plant glycosyltransferase UGT74AC1.ACS Catal 2020.10,3629-3639.
[0057] Example 2: Enhancing the function of the endoplasmic reticulum and promoting proper protein folding.
[0058] Genes regulating endoplasmic reticulum (ER) area were identified through NCBI searches, including PAH1 (phospholipid synthesis regulation), INO2 (ER expansion-related gene), and ICE2 (ER homeostasis regulation gene). Using CRISPR Cas9 gene editing, sgRNAs were designed, and the upstream and downstream homologous arms of the PAM region were amplified to knock out PAH1 in recombinant Saccharomyces cerevisiae strain M6, resulting in strain M7. The intrinsic promoter of INO2 in recombinant Saccharomyces cerevisiae strain M7 was replaced with the constitutive strong promoter P. TEF1 A recombinant Saccharomyces cerevisiae strain M8 achieving endoplasmic reticulum area expansion was obtained. The intrinsic promoter of ICE2 in the recombinant Saccharomyces cerevisiae strain M8 was replaced with the constitutive strong promoter P. TEF1 A recombinant Saccharomyces cerevisiae strain M9 was obtained, which achieved an expansion of the endoplasmic reticulum area.
[0059] The primers for constructing the homologous arms and PAM regions are shown in Table 4. PCR conditions are shown in Table 2.
[0060] Table 4 Primers required for homologous arm amplification and construction of plasmids containing the PAM region.
[0061] Example 3
[0062] To address the issues of low catalytic efficiency and low expression levels of P450 enzymes, a fusion expression method was first employed: fusing the P450 enzyme with its reductase. Enzyme fusion shortens the distance between the catalytic active site and the redox domain, promoting electron transfer and thus improving the catalytic efficiency of the P450 enzyme. The promoter P was amplified. GAL1 Amplify the localization protein PLN1, amplify gene fragments AtCPR2 and CYP87D18, and amplify the terminator T. CYC1 The gene expression cassette "P" of the fusion enzyme was constructed using overlap-derived PCR. GAL1 -PLN1-linker-AtCPR2-linker-CYP87D18-T CYC1 Furthermore, homologous arm fragments upstream and downstream of the PAM region at transposition site ty1 were amplified, and the homologous arms were constructed into linear gene fragments with the gene expression cassette using the overlap-derived PCR method.
[0063] The construction of the expression cassette, the amplification homologous arms, and the required primers are shown in Table 5. The PCR conditions are shown in Table 2.
[0064] Table 5 shows the primers required for constructing the expression cassette, amplifying homologous arms, and containing the PAM region.
[0065] The constructed pML104-PAM was then linked to the gene expression cassette “P GAL1-PLN1-linker-AtCPR2-linker-CYP87D18-T CYC1 "Transformed into competent cells of recombinant Saccharomyces cerevisiae strain M9, transformants with correct colony PCR results were selected for sequencing verification, and finally recombinant Saccharomyces cerevisiae strain M10 with compartmentalized expression pathway enzymes was obtained."
[0066] Example 4: Construction of recombinant strains for enhanced squalene utilization
[0067] To further improve the utilization rate of squalene, which is mainly encapsulated in lipid droplets, the strain was modified from two perspectives: subcellular localization of squalene epoxidase and the cofactors involved in the catalytic reaction. Through NCBI searching, an oil body storage protein derived from maize was selected as the localization protein. This protein has the function of localizing the target enzyme to lipid droplets and also has the characteristic of being able to fuse with proteins at both its N- and C-termini. Therefore, using oleosin as the localization protein allows for the attachment of the endogenous squalene epoxidase ERG1 from *Saccharomyces cerevisiae* to one end and the cofactor FAD synthase FAD1 to the other end, localizing both enzymes to lipid droplets while shortening the interaction distance between them, which is beneficial for the supply of cofactors. Therefore, the promoter fragment P was amplified. TEF1 Amplification of the endogenous squalene epoxidase ERG1 gene fragment in *Saccharomyces cerevisiae*, amplification of the codon-optimized localization protein oleosin, amplification of the endogenous FAD synthase FAD1 gene fragment in *Saccharomyces cerevisiae*, and amplification of the terminator T CYC1 Gene fragments were used to construct gene expression cassettes "P" using overlap-derived PCR. TEF1 -ERG1-linker-oleosin-linker-FAD1-T CYC1 The homologous arm fragments upstream and downstream of the PAM region at the IGR13 site were amplified, and the gene fragments connected to the expression cassettes by the homologous arms were obtained by overlap-derived PCR.
[0068] The constructed pML104-PAM and gene expression cassette were transformed into competent cells of recombinant Saccharomyces cerevisiae strain M10. Transformants with correct colony PCR results were selected for sequencing verification, and finally, recombinant Saccharomyces cerevisiae strain M11 with compartmentalized expression pathway enzymes was obtained.
[0069] The primers required for constructing the expression cassette, homologous arms, and plasmid containing the PAM region are shown in Table 6. PCR conditions are shown in Table 2.
[0070] Table 6 Primers required for fragment amplification, homologous arm amplification, and construction of plasmids containing the PAM region.
[0071] Example 5: Production of mogroside V by fermentation of recombinant brewer's yeast
[0072] The recombinant Saccharomyces cerevisiae strain that promotes mogroside V was streaked on YPD plates and incubated at 30°C until a large number of colonies grew.
[0073] Inoculate a loopful of a single colony into the seed culture medium and incubate at 30°C and 220 rpm for 18-20 h until the early logarithmic growth phase of the cells.
[0074] Inoculate the seed culture medium with 2% of the initial inoculum and incubate at 30℃ and 220 rpm for 96 h. Take samples of the bacterial culture every 12 h to measure the OD. 600 The remaining glucose level was checked. After 96 hours of incubation, the culture was stopped, transferred to a 50 mL centrifuge tube, and centrifuged at 8000 rpm for 5 minutes at room temperature. 1 mL of the supernatant was collected, and chromatographic-grade formic acid was added to bring the final formic acid concentration to 3% (v / v). The mixture was allowed to stand at 4°C for 4-8 hours to remove protein, then centrifuged at 8000 rpm for 5 minutes. 0.5 mL of the supernatant was collected, filtered through an aqueous filter membrane, and added to a liquid chromatography analysis bottle for yield determination.
[0075] Figure 1 shows the yields of mogroside V from different strains; Figure 2 shows the squalene content of M10 and M11; and Figure 3 shows the changes in mogroside V yields of M1 and M11 over fermentation time. The mogroside V yield of recombinant strain M11 was 26.33 mg / L, approximately five times that of the initially constructed mogroside V-synthesizing strain M07. The intracellular squalene content of M11 decreased significantly, indicating that enhancing squalene utilization is a key step in promoting mogroside V production. M11 reached its maximum yield at approximately 48 hours, a production cycle significantly shorter than the 96 hours of M07.
Claims
1. A method for constructing a yeast strain that promotes the de novo synthesis of mogroside V, characterized in that, The constructed gene expression frame P GAL1 -PLN1-linker-EPH3-T CYC1 P GAL1 -PLN1-linker-CYP87D18-T CYC1 P GAL1 -PLN1-linker-AtCPR2-T CYC1 P GAL1 -PLN1-linker-UGT74MG1-T CYC1 P GAL1 -PLN1-linker-UGTMS1 M7 -T CYC1 Recombinant engineered yeast strains were obtained by inserting enzymes into the genome of yeast strains that integrate pathway enzymes and enhance the expression of mevalonate pathway and squalene epoxidase.
2. The method for constructing a yeast strain that promotes de novo synthesis of mogroside V according to claim 1, characterized in that, in The yeast strain was inserted into the gene expression cassette P at site 720a. GAL1 -PLN1-linker-EPH3-T CYC1 Insert the gene expression cassette P into SAP155b GAL1 -PLN1-linker-CYP87D18-T CYC1 Insert the gene expression cassette P at site 1414a GAL1 -PLN1-linker-AtCPR2-T CYC1 Insert the gene expression cassette P at site 1260a. GAL1 -PLN1-linker-UGT74MG1-T CYC1 Insert the gene expression cassette P at site 805a. GAL1 -PLN1-linker-UGTMS1 M7 -T CYC1 .
3. The method for constructing a yeast strain that promotes de novo synthesis of mogroside V according to claim 2, characterized in that, The endoplasmic reticulum regulatory gene PAH1 in the recombinant engineered yeast strain was knocked out using the CRISPR Cas9 gene editing method, and the intrinsic promoter P of INO2 was removed. INO2 Replace with constitutive strong promoter P TEF1 And the inherent promoter P of ICE2 ICE2 Replace with constitutive strong promoter P TEF1 .
4. The method for constructing a yeast strain that promotes the de novo synthesis of mogroside V according to claim 3, characterized in that, in The transposition site ty1 of the recombinant engineered yeast strain is inserted into the gene expression cassette P of the fusion enzyme. GAL1 -PLN1-linker-AtCPR2-linker-CYP87D18-T CYC1 .
5. The method for constructing a yeast strain that promotes de novo synthesis of mogroside V according to claim 4, characterized in that, The expression box P TEF1 -ERG1-linker-oleosin-linker-FAD1-T CYC1 Insert the IGR13 site into the recombinant engineered yeast strain.
6. The method for constructing a yeast strain that promotes the de novo synthesis of mogroside V according to any one of claims 1-5, characterized in that, The engineered yeasts include, but are not limited to, Saccharomyces cerevisiae, Pichia pastoris, Pichia fermentata, Hansenula anomala, Yersinia lipolytica, Candida antarctica, Candida utilis, Candida tropicalis, Schizosaccharizoi saccharizoi, and Rhodotorula glutinis.
7. The recombinant yeast strain constructed according to the method for constructing yeast strains that promote de novo synthesis of mogroside V as described in any one of claims 1-6.
8. The application of the recombinant yeast strain according to claim 7 in the bio-fermentation production of mogrosides.
9. The method for producing mogrosides by fermentation using the recombinant yeast strain according to claim 7, characterized in that, The recombinant yeast strain was cultured in liquid YPD medium at 30°C and 220 r / min for 18 h in a shaker to obtain the fermentation seed liquid; The fermentation seed liquid was transferred into the fermentation medium at an inoculation rate of 2% and cultured at 30°C and 220 r / min for 96 h.
